Adobe PDF Download

Resilinc’s special report delivers a timely and strategic analysis of the evolving life sciences supply chain, spotlighting key trends in FDA PreCheck, continuous manufacturing, smart cold chain logistics, and cell and gene therapy (CGT) infrastructure. This 2025 supply chain outlook explores how regulatory changes and advanced technologies are reshaping how drugs are produced, monitored, and delivered. As biologics and CGTs introduce new demands, manufacturers and supply chain leaders must rapidly evolve to stay ahead of disruption and maintain operational agility. This report offers practical insights and actionable recommendations to build resilience and drive innovation in the face of accelerating change.